View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Haselmeier
21 December 2015

Haselmeier Self-Injection Devices Go Connected

Haselmeier has added connectivity to its devices portfolio with the announcement of its Axis-D-Connect disposable pen injector.

Haselmeier has partnered with the Austrian Institute of Technology GmbH (AIT) to equip its Axis-D platform pen with AIT’s cartridge fill level measurement system.

The patented technology provides an intuitive solution for patients, while creating an integrated device solution with various features, including device ID and authentication, electronic health record (EHR) integration and remote physician monitoring and interaction.

All features are designed to support better therapy adherence and improved patient outcomes. Based on near field communication (NFC), the fill level and dose measurement technology can be realised without the need to integrate a battery.

Using the highest possible degree of integration, a single chip enables small and cost effective solutions for various applications.

All measured data is transferred wirelessly to the end users’ mobile device, including smart phones, tablets or smart watches.

Using this technology keeps the patient and physician informed about the delivered dose and other drug-related information, and provides the basis for improving therapy outcomes.

Haselmeier chief strategy officer Frédéric Gabriel said: "This technology will allow Haselmeier to provide more integrated drug delivery solutions to its pharmaceutical partners across both our disposable and reusable injection device portfolios.

"Connected devices will define a new paradigm for improved treatment compliance and control of both chronic and acute diseases."

Austrian Institute of Technology Health & Environment Department business unit biomedical systems head Manfred Bammer said: "AIT and Haselmeier work together as strategic partners in order to bring forward the integration of the fill level measurement technology, and together we can define and develop connected injector solutions for customers and patients."

Haselmeier and AIT have straited user evaluation studies in order to fine-time user experience, according to the needs and requirements of different indication fields.

The flexibility of this technology and platform enables the adjustment of Axis-D Connect to user requirements and expectations.

Type 2 diabetes is a global health problem. According to expert estimates, the number of patients worldwide will increase by 48% by 2045.
The D-Flex injection pen can do more than previous pens. D-Flex can be configured for several fixed-dose values and is thus a variable fixed-dose pen.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology